- SGX Pharmaceuticals Announces Strategic Collaboration To Develop And Commercialize BCR-ABL Inhibitor
- How To Decorate Your Kitchen With A Mexican Theme
- Things to Know About Real Estate Loans
- Education Online – Your Gateway to Success
- Improve Your Eating Habits
- Are You Considering Bankruptcy? Wait!
- How To Choose Your Home Builder
- Get To Know Your Podcast Client
- Top 7 Article Writing Tools
- Hydrogen Powered Cars: The New Way To Go
bcrabl
SGX Pharmaceuticals Announces Strategic Collaboration To Develop And Commercialize BCR-ABL Inhibitor
Under the terms of the agreement, SGX will receive from Novartis $25 million in upfront payments and the purchase of SGX common stock. Along with success-based milestones, but excluding royalties, total payments to SGX could exceed $515 million, including a minimum of two years of research funding. The success of Gleevec(TM) (imatinib), the first targeted [...]